Early Access — free while we kick the tires
EdgarHawk

Kaplan Andrew T.

Director

Director 10% Owner

Latest: Director buying · April 2026

1 filing analyzed · 1 company · Latest 2026-04-20

Companies

Company Buys Sells Direction
Kailera Therapeutics, Inc. KLRA 2 0 Net buying

Activity

April 2026
high
Buy
8,398,438 shares
$134,375,008
Significance 8/10

Director Kaplan Andrew T. bought 8,398,438 shares of KLRA at $16.00 for $134.4M; post-buy holdings: 26.26M shares (cluster buy pattern with 4 other insiders in 14 days).

Director Kaplan Andrew T. purchased 8,398,438 shares at $16.00 on 2026-04-20, just 2 trading days after KLRA's recent listing, increasing his holdings by 47.0% from 17.86M to 26.26M shares. This transaction is part of a cluster buy pattern—4 other insiders also bought within the past 14 days—suggesting coordinated confidence in the newly public company's valuation. The current price of $24.61 is 53.8% above the transaction price, though this reflects only 2 days of post-IPO trading and should not be interpreted as a timing signal. Note that this filing involves a derivative-conversion transaction; the insider's complete position may extend beyond Table I holdings and requires review of Table II derivative securities for full context.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access